Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent before participating in the study.~2. Diagnosed with type 2 diabetes.~3. Inadequate glycemic control (screening: HbA1c ≥7.5% and ≤11.0% and FPG\<270 mg/dL (15mmol/L). At Day -4 visit, HbA1c ≥7.5% and ≤10.5%. and FPG\<270 mg/dL (15mmol/L)).~4. On a stable dose of insulin for 8 weeks or longer prior to screening.~5. If taking metformin, subjects should have been taking the same daily dose for 8 weeks or longer prior to screening.~6. Insulin type should be intermediate-acting or long-acting (basal) or premixed (premixed formulation may include short- or rapid-acting insulin as one component).~7. Body mass index ≤45 kg/m\^2.~Exclusion Criteria:~1. Women of childbearing potential unable or unwilling to use acceptable birth control.~2. Women who are pregnant or breastfeeding.~3. Symptoms of poorly controlled diabetes. including but not limited to, marked polyuria and polydipsia with greater than 10% weight loss during the last three months prior to screening or other signs and symptoms.~4. Significant cardiovascular history defined as: myocardial infarction, coronary angioplasty or bypass graft, valvular disease or repair, unstable clinical significant arrhythmia, unstable angina pectoris, transient ischemic attack, or cerebrovascular accident.~5. Congestive heart failure~6. Chronic or repeated intermittent corticosteroid treatment (subjects receiving stable doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled).~7. History of unstable or rapidly progressing renal disease.~8. History of alcohol or drug abuse within the previous year.~9. Unstable major psychiatric disorders.~10. History of hemoglobinopathies~11. Immunocompromised status~12. Severe liver disease.~13. In subjects treated with insulin alone a calculated creatinine clearance \<50 ml/min. In patients treated with insulin in combination with metformin a calculated creatinine clearance \<60 ml/min or serum creatinine \> 1.5 mg/dL in males or \> 1.4mg/dL in females.~14. Anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5mg (Type: EXPERIMENTAL): Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).